News Drug Formulary Safety Net Resources
Drug Formulary Categories and Charges Search HA Drug Formulary Self-financed Drugs Available for Purchase by Patients at HA Pharmacy How we evaluate new drugs Governance Drug Management Committee Drug Advisory Committee Drug Formulary Committee Drug & Therapeutics Committee Drug Selection Committee Expert Panel Medication Safety Committee Samaritan Fund Community Care Fund Drug Education HA Drug Formulary Management Manual Frequently Asked Questions Useful Links
HA Drug Formulary
Version 21.4 – with effect from 25 April 2026
  1. The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand.
  2. Some drugs may appear in more than one category due to different formulations and/or indications.
  3. The "Special" drugs will be prescribed as clinically indicated based on the specified indications.
  4. Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed on the HA Drug Formulary.
Drug classes
Result of:
Malignant disease & Immunosuppression
General Drugs Special Drugs Self-financed Items
with Safety Net		 Self-financed Items
without Safety Net
Malignant disease & Immunosuppression
General Drugs Special Drugs Self-financed Items
with Safety Net		 Self-financed Items
without Safety Net
CYTOTOXIC DRUGS
ACTINOMYCIN D ARSENIC TRIOXIDE ABEMACICLIB ACALABRUTINIB
ASPARAGINASE AZACITIDINE (VIDAZA) ACALABRUTINIB ALPELISIB
BLEOMYCIN BENDAMUSTINE AFATINIB ASCIMINIB
CALCIUM FOLINATE BLINATUMOMAB ALECTINIB ATEZOLIZUMAB
CAPECITABINE BUSULPHAN APALUTAMIDE BEVACIZUMAB
CARBOPLATIN CETUXIMAB ASCIMINIB BORTEZOMIB
CARMUSTINE CLADRIBINE ATEZOLIZUMAB CABOZANTINIB (CABOMETYX)
CHLORAMBUCIL CLOFARABINE AVELUMAB CAPMATINIB
CISPLATIN CRISANTASPASE (ASPARAGINASE ERW) AXITINIB CARFILZOMIB
CYCLOPHOSPHAMIDE DASATINIB AZACITIDINE (ONUREG) CETUXIMAB
CYTARABINE ERIBULIN AZACITIDINE (VIDAZA) DACOMITINIB
DACARBAZINE ERLOTINIB BELZUTIFAN DARATUMUMAB
DAUNORUBICIN EVEROLIMUS (AFINITOR) (OR EQUIV) BENDAMUSTINE DOSTARLIMAB
DOCETAXEL FLUDARABINE BEVACIZUMAB DOXORUBICIN (LIPOSOMAL)
DOXORUBICIN FRUQUINTINIB BORTEZOMIB DURVALUMAB
EPIRUBICIN GEFITINIB BRENTUXIMAB VEDOTIN ENFORTUMAB VEDOTIN
ETOPOSIDE IFOSFAMIDE BRIGATINIB EPCORITAMAB
FLUOROURACIL IMATINIB CARFILZOMIB ESTRAMUSTINE
GEMCITABINE MITOXANTRONE CETUXIMAB EVEROLIMUS (AFINITOR) (OR EQUIV)
HYDROXYUREA PEGASPARAGINASE CRIZOTINIB LENVATINIB
IDARUBICIN SORAFENIB DABRAFENIB NIRAPARIB (TOSYLATE)
IRINOTECAN TEMOZOLOMIDE DARATUMUMAB OBINUTUZUMAB
LOMUSTINE THIOTEPA DOXORUBICIN (LIPOSOMAL) OLAPARIB
MELPHALAN TOPOTECAN DURVALUMAB PACLITAXEL (ALBUMIN)
MERCAPTOPURINE TRASTUZUMAB ELRANATAMAB PAZOPANIB
MESNA TS-1 (OR EQUIV) ENCORAFENIB PEMBROLIZUMAB
METHOTREXATE VINORELBINE EVEROLIMUS (AFINITOR) (OR EQUIV) PERTUZUMAB + TRASTUZUMAB
MITOMYCIN GEMTUZUMAB REGORAFENIB
MITOTANE GILTERITINIB SACITUZUMAB GOVITECAN
OXALIPLATIN GLOFITAMAB SELPERCATINIB
PACLITAXEL IBRUTINIB SUNITINIB
PEMETREXED INOTUZUMAB OZOGAMICIN TRASTUZUMAB DERUXTECAN
PROCARBAZINE IPILIMUMAB TRASTUZUMAB EMTANSINE
THIOGUANINE ISATUXIMAB TRIFLURIDINE + TIPIRACIL
TRETINOIN IXAZOMIB VENETOCLAX
VINBLASTINE LAPATINIB
VINCRISTINE LENVATINIB
LORLATINIB
MIDOSTAURIN
NERATINIB
NILOTINIB
NIRAPARIB (TOSYLATE)
NIVOLUMAB
OBINUTUZUMAB
OLAPARIB
OSIMERTINIB
PACLITAXEL (ALBUMIN)
PALBOCICLIB
PANITUMUMAB
PAZOPANIB
PEMBROLIZUMAB
PERTUZUMAB
PERTUZUMAB + TRASTUZUMAB
POLATUZUMAB VEDOTIN
PONATINIB
RIBOCICLIB
RUXOLITINIB
SELINEXOR
SELUMETINIB
SUNITINIB
TEMOZOLOMIDE
TEPOTINIB
TORIPALIMAB
TRAMETINIB
TRASTUZUMAB
TRASTUZUMAB DERUXTECAN
TRASTUZUMAB EMTANSINE
TREMELIMUMAB
VENETOCLAX
ZANUBRUTINIB
DRUGS AFFECTING THE IMMUNE RESPONSE
AZATHIOPRINE ALEMTUZUMAB (LEMTRADA) BELUMOSUDIL LENALIDOMIDE
BCG ANTITHYMOCYTE IMMUNOGLOBULIN BENRALIZUMAB RITUXIMAB
THALIDOMIDE BASILIXIMAB CANAKINUMAB
CYCLOSPORIN A CLADRIBINE (MAVENCLAD)
CYCLOSPORIN A (NEORAL) INTERFERON GAMMA
CYCLOSPORIN A (TEVA) LENALIDOMIDE
DIMETHYL FUMARATE MEPOLIZUMAB
EVEROLIMUS (CERTICAN) (OR EQUIV) MOMELOTINIB
FINGOLIMOD POMALIDOMIDE
INTERFERON BETA RITUXIMAB
MYCOPHENOLATE SILTUXIMAB
NATALIZUMAB SIPONIMOD
OFATUMUMAB
PEGINTERFERON ALFA
RITUXIMAB
SIROLIMUS
TACROLIMUS
TERIFLUNOMIDE
SEX HORMONES AND HORMONE ANTAGONISTS IN MALIGNANT DISEASE
LETROZOLE ANASTROZOLE ABIRATERONE ABIRATERONE
MEDROXYPROGESTERONE ACETATE BICALUTAMIDE ENZALUTAMIDE DAROLUTAMIDE
MEGESTROL BUSERELIN FULVESTRANT ENZALUTAMIDE
OCTREOTIDE CYPROTERONE FULVESTRANT
SOMATOSTATIN DEGARELIX
TAMOXIFEN EXEMESTANE
FLUTAMIDE
GOSERELIN
LANREOTIDE
LEUPRORELIN
OCTREOTIDE
PASIREOTIDE
TRIPTORELIN
RADIOPHARMACEUTICALS
LUTETIUM OXODOTREOTIDE
LUTETIUM VIPIVOTIDE TETRAXETAN